Identification and structural elucidation of process impurities generated in the end-game synthesis of taranabant (MK-0364) via cyanuric chloride

Journal of Pharmaceutical and Biomedical Analysis

Volumn 49, Issue 3, 2009, Pages 702-710

  Chen, Yadan W ^a   Liu, Yong ^b   Novak, Thomas ^b   Frey, Lisa ^c   Campos, Kevin ^c   Klapars, Artis ^c   Chen, Cheng yi ^c   Phenix, Brain ^d  

^a Analytical Development and Commercialization API   (United States)

^b Early Development Analytical Research Merck   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d VERTEX PHARMACEUTICALS   (United States)

Author keywords

Cyanuric chloride; Impurity identification; MK 0364; Stability; Taranabant

Indexed keywords

CHLORINE DERIVATIVE; TARANABANT;

ARTICLE; CHEMICAL REACTION; DRUG DEGRADATION; DRUG IMPURITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; STRUCTURE ANALYSIS; ULTRAVIOLET RADIATION;

AMIDES; ANTI-OBESITY AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-LINKING REAGENTS; DRUG CONTAMINATION; DRUG STABILITY; INDICATORS AND REAGENTS; MASS SPECTROMETRY; PYRIDINES; RECEPTOR, CANNABINOID, CB1; REPRODUCIBILITY OF RESULTS; SPECTROPHOTOMETRY, ULTRAVIOLET; TRIAZINES;

EID: 61449103492     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2009.01.003     Document Type: Article

References (10)

1. Lin L.S., Lanza Jr. T.J., Jewell J.P., Liu P., Shah S.K., Qi H., Tong X., Wang J., Xu S.S., Fong T.M., Shen C.-P., Lao J., Xiao J.C., Shearman L.P., Stribling D.S., Rosko K., Strack A., Marsh D.J., Feng Y., Kumar S., Samuel K., Yin W., Van der Ploeg L.H.T., Goulet M.T., and Hagmann W.K. J. Med. Chem. 49 (2006) 7584-7587
2. Schnelle M., and Strasser F. Cannabis and Cannabinoids (2002), Haworth Integrative Healing Press, New York pp. 153-164
3. Drewnowski A., and Grinker J.A. Pharmacol. Biochem. Behav. 9 (1978) 619-630
4. Fong T.M., Guan X.-M., Marsh D.J., Shen C.-P., Stribling D.S., Rosko K.M., Lao J., Yu H., Feng Y., Xiao J.C., Van der Ploeg L.H.T., Goulet M.T., Hagmann W.K., Lin L.S., Lanza Jr. T.J., Jewell J.P., Liu P., Shah S.K., Qi H., Tong X., Wang J., Xu S.S., Francis B., Strack A.M., MacIntyre D.E., and Shearman L.P. J. Pharm. Exp. Ther. 321 (2007) 1013-1022
5. Chen C.-y., Frey L.F., Shultz S., Wallace D.J., Marcantonio K., Payack J.F., Vazquez E., Springfield S.A., Zhou G., Liu P., Kieczykowski G.R., Chen A.M., Phenix B.D., Singh U., Strine J., Izzo B., and Krska S.W. Org. Process Res. Dev. 11 (2007) 616-623
6. Haval K.P. Synlett 13 (2006) 2156-2157
7. European Medicines Agency (EMEA), ICH Topic Q3A (R1), Impurities in New Drug Substances, August 2002.
8. ICH Harmonised Tripartite Guideline, Q1A (R2), Stability Testing of New Drug Substances and Products, February 2003.
9. Bentley T.W., Llewellyn G., and McAlister J.A. J. Org. Chem. 61 (1996) 7927-7932
10. Kunishima M., and Zasshi Y. Pharm. Soc. Jpn. 128 (2008) 425-438